DOI: https://doi.org/10.37987/1997-9894.2015.8(194).222627

Алгоритм вибору нового перорального антикоагулянта у хворих з неклапанною фібриляцією передсердь

V. A. Skybchyk

Анотація


У статті обговорюються сучасні підходи до антитромботичної терапії при фібриляції передсердь (ФП). Розглянуто місце у цій стратегії нових пероральних антикоагулянтів (НОАК), антагоністів вітаміну К та антиагрегантів. Визначено алгоритм вибору НОАК у пацієнтів з ФП на основі даних доказової медицини (ключових досліджень RE-LY, ROCKET AF, ARISTOTLE, AVERROES).


Ключові слова


фібриляція передсердь; тромбоемболічні ускладнення; нові пероральні антикоагулянти; антагоністи вітаміну К; ацетилсаліцилова кислота; клопідогрель

Повний текст:

PDF

Посилання


Andersen K.K., Olsen T.S., Dehlendorff C., Kammersgaard L.P. Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors // Stroke. –2009. – Vol. 40 (6). – P. 2068–2072.

Camm A.J., Kirchhof P., Lip G.Y. et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC) // Europace. – 2010. – Vol. 12. – P. 1360–1420.

Camm A.J., Lip G.Y., De Caterina R. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association // Europace. – 2012. – Vol. 14. – P. 1385–1413.

Capodanno D., Lip G., Windecker S. et al. Triple antithrombotic therapy in atrial fibrillation patients with acute coronary syndromes or undergoing percutaneous coronary intervention or transcatheter aortic valve replacement //EuroIntervention. – 2015. – Vol. 10. – P. 1015–1021.

Connolly S. J., Pogue J., Hart R. G.et al. Effect of clopidogrel added to aspirin in Patients with atrial fibrillation // N. Engl. J. Med. – 2009. – Vol. 360. – P. 2066–2078.

Connoly S.J., Eikelboom J., Joyner C. et al AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation // N. Engl. J. Med. –2011. – Vol. 364. – P. 806–817.

Connolly S.J., Pogue J., Hart R. et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled Trial // Lancet. – 2006. – Vol. 367. – P. 1903–1912.

Connolly S.J., Ezekowitz M.D., Yusuf S. et al. Dabigatran versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. – 2009. – Vol. 361 (12). – P.1139–51.

Diener H.C. Pro: The novel oral anticoagulants should be used as 1st choice for secondary prevention in patients with atrial fibrillation // Thromb. Haemost. – 2013. – Vol. 110, №3. – P. 493–495.

FDA Drug Safety Communication: Pradaxa (dabigatran etexilate mesylate) should not be used in patients with mechanical prosthetic heart valves. – Available at: http://www.fda.gov/Drugs/DrugSafe- ty/ucm332912.htm. Date of access 18/04/2013.

Granger C.B., Alexander J.H., McMurray J.J.V. et al. ARISTOTLE Comittees and Investigators .Apixaban versus warfarin in patients with atrial fibrillation // N. Engl. J. Med. – 2011. – Vol. 365 (11). – P. 981–992.

Harrington A.R., Armstrong E.P., Nolan P.E. Jr., Malone D.C. Cost-effectiveness of apixaban, dabigatran, rivaroxaban, and warfarin for stroke prevention in atrial fibrillation // Stroke. – 2013 Apr 2 [Epub ahead of print].

Hart R.G., Pearce L.A., Aguilar M.I. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have non-valvular atrial fibrillation // Ann. Intern. Med. – 2007. – Vol. 146. – P. 857–867.

Lip G.Y., Windecker S., Huber K. et al. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS) // Eur. Heart J. – Advance Access published August 25, 2014.

Lloyd-Jones D., Adams R., Carnethon M. et al. Heart disease and stroke statistics 2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee // Circulation. – 2009. – Vol. 119. – P. 21–181.

Patel M.R., Mahaffey K.W., Garg J. et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation // N. Engl. J. Med. – 2011. – Vol. 365 (10). – P. 883–891.

Price J., Hynes M., Labinaz M. et al. Mechanical valve thrombosis with dabigatran // J. Am. Coll. Cardiol. – 2012. – Vol. 60 (17). – P. 1710–1711.

Ruff C.T. et al. // Lancet. – 2013. – doi: 10.1016/S0140-6736(13)62343-0.

Wallentin L., Yusuf S., Ezekowitz M. D. et al. Efficasy and Safety of Dabigatran compared with Warfarin at different levels of INR control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial // Lancet. – 2010. – Vol. 376. – P. 975–983.

Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study // Stroke. – 1991. – Vol. 22. – P. 983–988.

Wolf P.A., Abbott R.D., Kannel W.B. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study // Arch. Intern. Med. – 1987. – Vol. 147. – P. 1561–1564.


Посилання

  • Поки немає зовнішніх посилань.